P685 Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials
Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Chinyu Su(Pfizer (United States)), Marco DiBonaventura(Kantar Health (United States)), Alessandro Armuzzi, Brian Bressler(University of British Columbia), Deborah Woodworth(Pfizer (United States)), Eric S. Maller(Pfizer (United States)), Heng Fan(Ningbo University Affiliated Hospital), Leonardo Salese(Johnson & Johnson (United States))
Cited by 3
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k